Chemotherapy-induced nausea and vomiting in an oncologist's practice. How can nausea and vomiting be prevented?
OncoReview · 30.07.2025 · 15 (2(58)) · 36-40
DOI: 10.24292/01.or.152011025 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, online erschienen am 30.07.2025. Verfasst von Agnieszka Jagiełło-Gruszfeld.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced nausea and vomiting (CINV) affects 70–80% of patients and significantly reduces quality of life and complicates treatment. Prevention is more effective than treatment – once symptoms develop, they are more difficult to control and can cause anticipatory nausea. The most important drug classes used for prophylaxis are: 5-HT3-RA s (e.g., ondansetron, palonosetron), NK1-RA s (aprepitant, netupitant), dexamethasone, and olanzapine. Modern regimens (e.g., NEPA, palonosetron) are more effective in preventing delayed and long-term CINV.
Zitieren
APA
Jagiełło-Gruszfeld, A. (2025). Chemotherapy-induced nausea and vomiting in an oncologist's practice. How can nausea and vomiting be prevented?. OncoReview, 15(2(58)), 36-40. https://doi.org/10.24292/01.or.152011025
Vancouver
Jagiełło-Gruszfeld A. Chemotherapy-induced nausea and vomiting in an oncologist's practice. How can nausea and vomiting be prevented?. OncoReview. 2025;15(2(58)):36-40. doi:10.24292/01.or.152011025
BibTeX
@article{JagieoGruszfeld2025,
author = {Jagiełło-Gruszfeld, Agnieszka},
title = {Chemotherapy-induced nausea and vomiting in an oncologist's practice. How can nausea and vomiting be prevented?},
journal = {OncoReview},
year = {2025},
volume = {15},
number = {2(58)},
pages = {36--40},
doi = {10.24292/01.or.152011025}
}
EUVIMED